Linked Data API

Filter

These are the filters currently being used to limit the search results. Click on the remove filter icon to remove the filter.

answer › question first answered	2018-11-21T14:39:19.47Z
answer › answer text	%3Cp%3EThe Specialised Respiratory Clinical Reference Group %28CRG%29 is maintaining an oversight of the need to develop a service specification and selection of providers to offer specialised expertise and management advice for patients diagnosed with alpha1 antitrypsin deficiency %28AATD%29.%3C%2Fp%3E%3Cp%3E %3C%2Fp%3E%3Cp%3EThe CRG has recommended that NHS England wait until it is clear on the outcome of the National Institute for Health and Care Excellence %28NICE%29 Highly Specialised Technologies evaluation of human alpha1-proteinase inhibitor for treating emphysema in adults with documented severe AATD %5BID856%5D until this development is taken forward.%3C%2Fp%3E%3Cp%3E %3C%2Fp%3E%3Cp%3ENICE has not yet published final guidance and recently consulted on its draft guidance. NICE%E2%80%99s evaluation committee is due to meet again to consider its recommendations in spring next year. This is to enable the company that makes the alpha1-proteinase inhibitor to prepare and submit additional information for consideration by the committee.%3C%2Fp%3E
answer › answering member constituency	Gosport

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are shown at the top of the list. Click on remove this sort to remove a sort and or to reverse the current sort order. Click on the remove all sorting icon to remove all the sorting. Note that sorting can significantly slow down the loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined views, but starred properties are always present no matter what the view. You can star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

Items per page

Choose how many items to view on each page. The more items you view, the longer the page will take to load.

Show Search Form

Search Results

registered interest

date

exactly:

or between:
and

answering body

answering dept id

answering dept short name

answering dept sort name

hansard heading

house id

legislature


pref label

question text

tabling member constituency

tabling member printed

uin

answer

is ministerial correction

date of answer

exactly:

or between:
and

answer text

answering member constituency

answering member printed

question first answered

answering member


label

tabling member


label

1006995

registered interest

date

14/11/2018

answering body

Department of Health and Social Care

answering dept id

answering dept short name

Health and Social Care

answering dept sort name

Health and Social Care

hansard heading

AAT Deficiency

house id

legislature

25259

pref label	House of Commons

question text

To ask the Secretary of State for Health and Social Care, when he plans a NHS service for alpha-1 to improve patients' access to coordinated multi-disciplinary clinical expertise, which was approved by the Department's Prescribed Specialised Services Advisory Group in March 2016, to commence.

tabling member constituency

Birkenhead

tabling member printed

Frank Field

uin

191307

answer

is ministerial correction

date of answer

21/11/2018

answer text

The Specialised Respiratory Clinical Reference Group (CRG) is maintaining an oversight of the need to develop a service specification and selection of providers to offer specialised expertise and management advice for patients diagnosed with alpha1 antitrypsin deficiency (AATD). The CRG has recommended that NHS England wait until it is clear on the outcome of the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies evaluation of human alpha1-proteinase inhibitor for treating emphysema in adults with documented severe AATD [ID856] until this development is taken forward. NICE has not yet published final guidance and recently consulted on its draft guidance. NICE’s evaluation committee is due to meet again to consider its recommendations in spring next year. This is to enable the company that makes the alpha1-proteinase inhibitor to prepare and submit additional information for consideration by the committee.

answering member constituency

Gosport

answering member printed

Caroline Dinenage

question first answered

21/11/2018 14:39:19

answering member

4008

label	Biography information for Dame Caroline Dinenage

tabling member

478

label	Biography information for Lord Field of Birkenhead